To see the other types of publications on this topic, follow the link: Antitumor.

Journal articles on the topic 'Antitumor'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antitumor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Shtemenko, A. V., and N. I. Shtemenko. "Rhenium–platinum antitumor systems." Ukrainian Biochemical Journal 89, no. 2 (April 24, 2017): 5–30. http://dx.doi.org/10.15407/ubj89.02.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Didenko, G. V. "ANTITUMOR AND ANTIMETASTATIC EFFICIENCY OF ANTITUMOR VACCINE AND AMIXIN COMBINED ACTION IN MICE WITH LEWIS LUNG CARCINOMA." Biotechnologia Acta 9, no. 3 (June 2016): 76–83. http://dx.doi.org/10.15407/biotech9.03.076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Asche, Christian, and Martine Demeunynck. "Antitumor Carbazoles." Anti-Cancer Agents in Medicinal Chemistry 7, no. 2 (March 1, 2007): 247–67. http://dx.doi.org/10.2174/187152007780058678.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Scuderi, N., and M. G. Onesti. "Antitumor Agents." Annals of Plastic Surgery 32, no. 1 (January 1994): 39–44. http://dx.doi.org/10.1097/00000637-199401000-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

NISHIKAWA, KIYOHIRO, CHIEKO SHIBASAKI, KATSUTOSHI TAKAHASHI, TERUYA NAKAMURA, TOMIO TAKEUCHI, and HAMAO UMEZAWA. "Antitumor activity of spergualin, a novel antitumor antibiotic." Journal of Antibiotics 39, no. 10 (1986): 1461–66. http://dx.doi.org/10.7164/antibiotics.39.1461.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Akima, Kazuo, Hisashi Ito, Yuhei Iwata, Kayoko Matsuo, Nobutoshi Watari, Mitsuo Yanagi, Hiroo Hagi, et al. "Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity." Journal of Drug Targeting 4, no. 1 (January 1996): 1–8. http://dx.doi.org/10.3109/10611869609046255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Maksimov, Maksim Leonidovich, and Malika Anarbekovna Ismailova. "Adverse reactions during chemotherapy: skin toxicity." Vrač skoroj pomoŝi (Emergency Doctor), no. 9 (September 1, 2020): 28–64. http://dx.doi.org/10.33920/med-02-2009-01.

Full text
Abstract:
Chemotherapy of oncological diseases is associated with high toxicity. The occurrence of various toxic reactions during the use of antitumor drugs is explained by the fact that most antitumor medicines are not strictly specific, therefore, their effect can extend not only to tumor cells, but also to normal cells, especially to tissues with rapid proliferation. All antitumour agents have skin toxicity in one form or another. However, for some chemotherapeutic agents, skin toxicity is a kind of «reflection» of certain mechanisms of drugs action, and, in most cases, the severity of dermatological reactions correlates with the effectiveness of chemotherapy. Dermatological toxicity deserves special attention, as it affects the quality of life of cancer patients and, in some cases, may require a dose reduction or even cancellation of chemotherapy. This article presents current data on the mechanisms of development of skin toxicity of routine chemotherapeutic agents, growth factor inhibitors and some antitumor antibiotics, its correction and prevention opportunities.
APA, Harvard, Vancouver, ISO, and other styles
8

Torres, Nicolas, María Victoria Regge, Florencia Secchiari, Adrián David Friedrich, Raúl Germán Spallanzani, Ximena Lucía Raffo Iraolagoitia, Sol Yanel Núñez, et al. "Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein." Journal for ImmunoTherapy of Cancer 8, no. 1 (June 2020): e000233. http://dx.doi.org/10.1136/jitc-2019-000233.

Full text
Abstract:
BackgroundNatural killer and cytotoxic CD8+T cells are major players during antitumor immunity. They express NKG2D, an activating receptor that promotes tumor elimination through recognition of the MHC class I chain-related proteins A and B (MICA and MICB). Both molecules are overexpressed on a great variety of tumors from different tissues, making them attractive targets for immunotherapy. However, tumors shed MICA and MICB, and the soluble forms of both (sMICA and sMICB) mediate tumor-immune escape. Some reports indicate that anti-MICA antibodies (Ab) can promote the restoration of antitumor immunity through the induction of direct antitumor effects (antibody-dependent cell-mediated cytotoxicity, ADCC) and scavenging of sMICA. Therefore, we reasoned that an active induction of anti-MICA Ab with an immunogenic protein might represent a novel therapeutic and prophylactic alternative to restore antitumor immunity.MethodsWe generated a highly immunogenic chimeric protein (BLS-MICA) consisting of human MICA fused to the lumazine synthase fromBrucellaspp (BLS) and used it to generate anti-MICA polyclonal Ab (pAb) and to investigate if these anti-MICA Ab can reinstate antitumor immunity in mice using two different mouse tumors engineered to express MICA. We also explored the underlying mechanisms of this expected therapeutic effect.ResultsImmunization with BLS-MICA and administration of anti-MICA pAb elicited by BLS-MICA significantly delayed the growth of MICA-expressing mouse tumors but not of control tumors. The therapeutic effect of immunization with BLS-MICA included scavenging of sMICA and the anti-MICA Ab-mediated ADCC, promoting heightened intratumoral M1/proinflammatory macrophage and antigen-experienced CD8+T cell recruitment.ConclusionsImmunization with the chimeric protein BLS-MICA constitutes a useful way to actively induce therapeutic anti-MICA pAb that resulted in a reprogramming of the antitumor immune response towards an antitumoral/proinflammatory phenotype. Hence, the BLS-MICA chimeric protein constitutes a novel antitumor vaccine of potential application in patients with MICA-expressing tumors.
APA, Harvard, Vancouver, ISO, and other styles
9

Gomi, Katsushige, Eiji Kobayashi, Katsunori Miyoshi, Tadashi Ashizawa, Akihiko Okamoto, Tatsuhiro Ogawa, Shigeo Katsumata, Akira Mihara, Masami Okabe, and Tadashi Hirata. "Anticellular and Antitumor Activity of Duocarmycins, Novel Antitumor Antibiotics." Japanese Journal of Cancer Research 83, no. 1 (January 1992): 113–20. http://dx.doi.org/10.1111/j.1349-7006.1992.tb02360.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zhang, Lingbing, Dongdong Feng, Lynda X. Yu, Kangla Tsung, and Jeffrey A. Norton. "Preexisting antitumor immunity augments the antitumor effects of chemotherapy." Cancer Immunology, Immunotherapy 62, no. 6 (April 18, 2013): 1061–71. http://dx.doi.org/10.1007/s00262-013-1417-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

KOSUGE, TAKUO, MASAMI YOKOTA, KIYOSHI SUGIYAMA, TOSUKE YAMAMOTO, MUYUN NI, and SHUCHANG YAN. "Studies on Antitumor Activities and Antitumor Principles of Chinese Herbs. I. Antitumor Activities of Chinese Herbs." YAKUGAKU ZASSHI 105, no. 8 (1985): 791–95. http://dx.doi.org/10.1248/yakushi1947.105.8_791.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Shtemenko, N. I., D. E. Kytova, O. V. Berzenina, O. I. Hrabovska, and A. V. Shtemenko. "New formulation and activity of rhenium-platinum antitumor system." Ukrainian Biochemical Journal 94, no. 3 (October 4, 2022): 92–98. http://dx.doi.org/10.15407/ubj94.03.092.

Full text
Abstract:
Two-component Rhenium-Platinum system (Re-Pt system) is based on administration of a cluster dirhenium(III) compound and cisplatin to tumor bearing animals followed by a significant antitumor effect and decreased toxic effect of cisplatin on normal cells. The aim of this work was to obtain solid lipid nanoparticles (SLN) from surface lipids (waxes) of Chelidonium majus L. (Papaveraceae) leaves and to estimate whether capsulation of dirhenium(III) as a component of the Re-Pt system into SLN will affect its antitumor activity and red blood cells (RBC) morphology in a rat model of Guerin’s carcinoma growth. Fourier-transform infrared spectroscopy, gas-liquid chromatography, microscopy, light scattering were used in the research. Solid lipid nanoparticles were obtained, characterized, loaded with cluster dirhenium(III) and being introduced together with cisplatin to rats with Guerin’s carcinoma resulted in RBC morphology preservation and a significant decrease in tumor weight. It was concluded that the lipid coating of the rhenium cluster compound did not reduce the antitumor effect of the Re-Pt system and protected RBC from toxic cisplatin influence­. A new formulation of the Re-Pt system is proposed. Keywords: carcinoma, rhenium cluster compound, rhenium-platinum antitumor system, solid lipid nanoparticles, surface lipids
APA, Harvard, Vancouver, ISO, and other styles
13

Lin, J. Y. "Antitumor Protein: Abrin." Journal of Toxicology: Toxin Reviews 13, no. 3 (January 1994): 219–28. http://dx.doi.org/10.3109/15569549409089961.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Ferrarelli, L. K. "Engineering antitumor activity." Science 353, no. 6307 (September 29, 2016): i—1510. http://dx.doi.org/10.1126/science.353.6307.1509-i.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Rusk, Nicole. "Antitumor T cells." Nature Methods 16, no. 1 (December 20, 2018): 19. http://dx.doi.org/10.1038/s41592-018-0271-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Foley, John F. "Highlight: Antitumor strategies." Science Signaling 10, no. 500 (October 10, 2017): eaaq1397. http://dx.doi.org/10.1126/scisignal.aaq1397.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Fiallo, Marina M. L., Henryk Kozlowski, and Arlette Garnier-Suillerot. "Mitomycin antitumor compounds." European Journal of Pharmaceutical Sciences 12, no. 4 (February 2001): 487–94. http://dx.doi.org/10.1016/s0928-0987(00)00200-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

KONISHI, Masataka. "Novel antitumor antibiotics." Kagaku To Seibutsu 26, no. 2 (1988): 90–101. http://dx.doi.org/10.1271/kagakutoseibutsu1962.26.90.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Krapcho, A. P., and E. Menta. "Antitumor aza-anthrapyrazoles." Drugs of the Future 22, no. 6 (1997): 641. http://dx.doi.org/10.1358/dof.1997.022.06.418670.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Nagamura, Satoru, and Hiromitsu Saito. "Antitumor antibiotics: Duocarmycins." Chemistry of Heterocyclic Compounds 34, no. 12 (December 1998): 1386–405. http://dx.doi.org/10.1007/bf02317808.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Motohashi, Noboru, Lester A. Mitscher, and Roger Meyer. "Potential antitumor phenoxazines." Medicinal Research Reviews 11, no. 3 (May 1991): 239–94. http://dx.doi.org/10.1002/med.2610110302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Houlihan, William J., Matthias Lohmeyer, Paul Workman, and Seung H. Cheon. "Phospholipid antitumor agents." Medicinal Research Reviews 15, no. 3 (May 1995): 157–223. http://dx.doi.org/10.1002/med.2610150302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Crompton, Joseph G., David Clever, Raul Vizcardo, Mahendra Rao, and Nicholas P. Restifo. "Reprogramming antitumor immunity." Trends in Immunology 35, no. 4 (April 2014): 178–85. http://dx.doi.org/10.1016/j.it.2014.02.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

ISHIZEKI, SEIJI, MARI OHTSUKA, KAZUHIKO IRINODA, KEN-ICHI KUKITA, KATSUHIKO NAGAOKA, and TOSHIAKI NAKASHIMA. "Azinomycins A and B, new antitumor antibiotics. III. Antitumor activity." Journal of Antibiotics 40, no. 1 (1987): 60–65. http://dx.doi.org/10.7164/antibiotics.40.60.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

ZHEN, YONG-SU, XIU-YING MING, BIN YU, TOSHIO OTANI, HITOSHI SAITO, and YUJI YAMADA. "A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity." Journal of Antibiotics 42, no. 8 (1989): 1294–98. http://dx.doi.org/10.7164/antibiotics.42.1294.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Villa-Pulgarin, Janny A., Constain H. Salamanca, Jose Oñate-Garzón, and Ruben E. Varela-M. "Antitumor Activity In Vitro Provided by N-Alkyl-Nitroimidazole Compounds." Open Medicinal Chemistry Journal 14, no. 1 (July 30, 2020): 45–48. http://dx.doi.org/10.2174/1874104502014010045.

Full text
Abstract:
Background: Cancer is one of the most common diseases in the world, with over 18 million new cases estimated in 2018. Many of the drugs used for cancer can have significant adverse effects and variable effectiveness. Nitroimidazoles are prodrugs that usually have shown antimicrobial activity specifically antiparasitic. However, its antitumor activity in vitro has barely been explored. Objective: The aim of this study is to determine the influence of the length of the substituted N-alkyl chain in the imidazole ring on the antitumor activity in vitro. Methods: Four nitroimidazoles were obtained by chemical synthesis varying the length of the substituted N-alkyl chain from methyl to butyl. The antitumor activity of N-alkyl-nitroimidazoles was evaluated by MTT assay employing two tumor cell lines (MDA-MB231 and A549). Results: In this study, it was reported that N-alkyl nitroimidazoles exhibited an LC50 as low as 16.7 µM in breast tumor cells MDA-MB231 while in normal Vero kidney cells, the LC50 was around 30 µM. It was also reported that the length of the substituted N-Alkyl chain in the imidazole ring affects the antitumoral activity in A549 lung cells. Conclusion: Increasing the length of the substituted N-Alkyl chain in the imidazole ring decreased the antitumor activity against only A549 cancer cells. N-alkyl nitroimidazoles exhibited considerable selectivity towards tumor cell lines.
APA, Harvard, Vancouver, ISO, and other styles
27

Sánchez-Quesada, Cristina, Francisco Gutiérrez-Santiago, Carmen Rodríguez-García, and José J. Gaforio. "Synergistic Effect of Squalene and Hydroxytyrosol on Highly Invasive MDA-MB-231 Breast Cancer Cells." Nutrients 14, no. 2 (January 7, 2022): 255. http://dx.doi.org/10.3390/nu14020255.

Full text
Abstract:
Several studies relate Mediterranean diet and virgin olive oil (VOO) intake with lower risk of several chronic diseases, including breast cancer. Many of them described antitumor properties of isolated minor compounds present in VOO, but beneficial properties of VOO arise from the effects of all its compounds acting together. The aim of the present study was to test the antitumor effects of two minor compounds from VOO (hydroxytyrosol (HT) and squalene (SQ)) on highly metastatic human breast tumor cells (MDA-MB-231) when acting in combination. Both isolated compounds were previously analyzed without showing any antitumoral effect on highly invasive MDA-MB-231 breast cancer cells, but the present results show that HT at 100 µM, combined with different concentrations of SQ, could exert antitumor effects. When they are combined, HT and SQ are able to inhibit cell proliferation, promoting apoptosis and DNA damage in metastatic breast cancer cells. Therefore, our results suggest that the health-promoting properties of VOO may be due, at least in part, to the combined action of these two minor compounds.
APA, Harvard, Vancouver, ISO, and other styles
28

Wang, Xinmin, Ying Wang, Jialiang Hu, and Hanmei Xu. "An antitumor peptide RS17‐targeted CD47, design, synthesis, and antitumor activity." Cancer Medicine 10, no. 6 (February 24, 2021): 2125–36. http://dx.doi.org/10.1002/cam4.3768.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

SMITKA, T. A., R. H. BUNGE, J. H. WILTON, G. C. HOKANSON, J. C. FRENCH, HE CUN-HENG, and JON CLARDY. "PD 116,152, a new phenazine antitumor antibiotic. Structure and antitumor activity." Journal of Antibiotics 39, no. 6 (1986): 800–803. http://dx.doi.org/10.7164/antibiotics.39.800.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Huang, Haochao, Haiwei Wu, Yongrui Huang, Shuangying Zhang, Yuetwai Lam, and Ningjian Ao. "Antitumor activity and antitumor mechanism of triphenylphosphonium chitosan against liver carcinoma." Journal of Materials Research 33, no. 17 (August 14, 2018): 2586–97. http://dx.doi.org/10.1557/jmr.2018.255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Wang, Yongfeng, Malcolm F. G. Stevens, Tze-ming Chan, Donald DiBenedetto, Zhe-xing Ding, Dinesh Gala, Donald Hou, et al. "Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide." Journal of Organic Chemistry 62, no. 21 (October 1997): 7288–94. http://dx.doi.org/10.1021/jo970802l.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

NISHIMURA, MAKOTO, HIROHISA NAKADA, IKUO KAWAMURA, TAMOTSU MIZOTA, KYOICHI SHIMOMURA, KUNIO NAKAHARA, TOSHIO GOTO, ISAMU YAMAGUCHI, and MASAKUNI OKUHARA. "A new antitumor antibiotic, FR900840. III. Antitumor activity against experimental tumors." Journal of Antibiotics 42, no. 4 (1989): 553–57. http://dx.doi.org/10.7164/antibiotics.42.553.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Kalechman, Y., A. Shani, S. Dovrat, J. K. Whisnant, K. Mettinger, M. Albeck, and B. Sredni. "The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma." Journal of Immunology 156, no. 3 (February 1, 1996): 1101–9. http://dx.doi.org/10.4049/jimmunol.156.3.1101.

Full text
Abstract:
Abstract The immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate (AS101) has been shown to possess antitumoral properties in several murine models. In the present study, we demonstrate a synergistic in vivo antitumor effect of AS101 and Taxol against early stage Madison 109 lung adenocarcinoma. Treatment with optimal doses of Taxol (25 and 17 mg/kg) and AS101 (0.5 mg/kg) resulted in 66.6 and 43.3% cures. We propose that the antitumor effect is the result of both a direct and indirect effect of the drugs on tumor cells. AS101 and Taxol directly inhibited clonogenicity of M109 cells in a synergistic dose-dependent manner. Exposure of M109 cells to clinically achievable concentrations of Taxol and AS101 produced a synergistic internucleosomal DNA fragmentation associated with programmed cell death. We suggest that AS101 renders tumor cells more susceptible to chemotherapy in general and to Taxol in particular, partly by increasing the wild-type p53 protein expression that is required for efficient execution of the death program. Moreover, we demonstrate a synergistic effect of AS101 and Taxol in increasing the tumoricidal activity of macrophages. This activity is produced by nitric oxide secretion. The synergistic antitumoral effects of AS101 and Taxol were partly ablated both in vitro and in vivo by inhibition of nitric oxide synthase. These findings indicate that AS101 in combination with Taxol may be a promising antitumor drug, and illustrate the mechanism of action of both drugs when acting synergistically. Phase II clinical trials have been initiated using AS101 in combination with Taxol.
APA, Harvard, Vancouver, ISO, and other styles
34

Singh, Priyanshi, T. S. Naqvi, and R. K. Singh. "Antioxidant and Antitumor Activities of Leaf Extract of Eclipta Alba." Universities' Journal of Phytochemistry and Ayurvedic Heights I, no. 32 (June 18, 2022): 1–4. http://dx.doi.org/10.51129/ujpah-2022-32-1(3).

Full text
Abstract:
Abstract –Medicinal plants are nature’s hidden and unexplored treasures (nature’s pharmacy) for humanity since times immemorial. The plant EcliptaAlba has many medicinal value used in the traditional Ayurvedic and Unani System.EcliptaAlba (L.) commonly known as bhringraj as well as false daisy, a species of plant in the family Asteraceae.This herb contains many bioactive components such as coumestans i.e. wedelolactone anddimethyl wedelolactone, flavonoids, stero- ids, etc. We have examined it antioxidant activity through DPPH & reducing power assay and we got in it total phenolic content, flavonoids and sterol as good antioxident agents. The antioxidant activity was assessed through DPPH and reducing power assay, which was explained in terms of effective concentration EC50/IC50.
APA, Harvard, Vancouver, ISO, and other styles
35

Vargas-Castro, Karen C., Ana M. Puebla Pérez, Irma I. Rangel-Salas, Jorge I. Delgado-Saucedo, José B. Pelayo-Vázquez, Elvia Becerra-Martínez, Alejandro A. Peregrina-Lucano, Raul R. Quiñonez-Lopez, Gabriela J. Soltero-Reynoso, and Sara A. Cortes-Llamas. "Antitumor Effect of Zwitterions of Imidazolium Derived from L-methionine in BALB/c Mice with Lymphoma L5178Y." Medicinal Chemistry 17, no. 1 (December 29, 2020): 33–39. http://dx.doi.org/10.2174/1573406415666191206093754.

Full text
Abstract:
Background: In the therapy of cancer, several treatments have been designed using nanomaterials, among which gold nanoparticles (AuNPs) have been featured as a promising antitumoral agent. Our research group has developed the synthesis of gold nanoparticles L-AuNPs and D-AuNPs stabilized with zwitterions of imidazolium (L-1 and D-1) derived from L-methionine and D-methionine. Because the stabilizer agent is chiral, we observed through circular dichroism that AuNPs also present chirality; such chirality as well as the fact that the stabilizing agent contains fragments of methionine and imidazolium that are commonly involved in biological processes, opens up the possibility that this system may have biological compatibility. Additionally, the presence of methionine in the stabilizing agent opens the application of this system as a possible antitumor agent because methionine is involved in methylation processes of molecules such as DNA. Objective: The aim of this research is the evaluation of the antitumor activity of gold nanoparticles stabilized with zwitterions of imidazolium (L-AuNPs) derived from L-methionine in the model of BALB/c mice with lymphoma L5178Y. Methods: Taking as a parameter cell density, the evaluation of the inhibitory effect of L-AuNPs was carried out with a series of in vivo tests in BALB/c type mice; three groups of five mice each were formed (Groups 1, 2 and 3); all mice were i.p. inoculated with the lymphoblast murine L5178Y. Group 1 consisted of mice without treatment. In the Groups 2 and 3 the mice were treated with L-AuNPs at 0.3 mg/Kg on days 1, 7 and 14 by orally and intraperitonally respectively. Results: These results show low antitumor activity of these gold nanoparticles (L-NPsAu) but interestingly, the imidazolium stabilizing agent of gold nanoparticle (L-1) displayed promising antitumor activity. On the other hand, the enantiomer of L-1, (D-1) as well as asymmetric imidazole derivate from L-methionine (L-2), do not exhibit the same activity as L-1. Conclusion: The imidazolium stabilizing agent (L-1) displayed promising antitumor activity. Modifications in the structure of L-1 showed that, the stereochemistry (like D-1) and the presence of methionine fragments (like L-2) are determinants in the antitumor activity of this compound.
APA, Harvard, Vancouver, ISO, and other styles
36

Dimopoulos, Meletios-Athanassios, Constantine S. Mitsiades, Kenneth C. Anderson, and Paul G. Richardson. "Tanespimycin as Antitumor Therapy." Clinical Lymphoma Myeloma and Leukemia 11, no. 1 (February 2011): 17–22. http://dx.doi.org/10.3816/clml.2011.n.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Jones, G., and F. Fouad. "Designed Enediyne Antitumor Agents." Current Pharmaceutical Design 8, no. 27 (December 1, 2002): 2415–40. http://dx.doi.org/10.2174/1381612023392810.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Nathan, James A. "Metabolite-driven antitumor immunity." Science 377, no. 6614 (September 30, 2022): 1488–89. http://dx.doi.org/10.1126/science.ade3697.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Kasakura, Shinpei. "Cytokines with antitumor activity." Japanese Journal of Clinical Immunology 10, no. 1 (1987): 1–9. http://dx.doi.org/10.2177/jsci.10.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Zverev, Y. F. "Antitumor activity of flavonoids." Bulletin of Siberian Medicine 18, no. 2 (August 11, 2019): 181–94. http://dx.doi.org/10.20538/1682-0363-2019-2-181-194.

Full text
Abstract:
This review of the literature is devoted to the consideration of mechanisms of the antitumor effect of flavonoids. The anticanceromatous effect of flavonoids is discussed in the context of their impact on the main stages of development of malignant tumor cells. At the same time, the influence of flavonoids on the activity of protein kinases, metalloproteinases, apoptosis, angiogenesis and the cell cycle of tumor cells is considered in detail.
APA, Harvard, Vancouver, ISO, and other styles
41

Kim, Seung Jo, Min Chul Choi, Jong Min Park, and An Sik Chung. "Antitumor Effects of Selenium." International Journal of Molecular Sciences 22, no. 21 (October 31, 2021): 11844. http://dx.doi.org/10.3390/ijms222111844.

Full text
Abstract:
Functions of selenium are diverse as antioxidant, anti-inflammation, increased immunity, reduced cancer incidence, blocking tumor invasion and metastasis, and further clinical application as treatment with radiation and chemotherapy. These functions of selenium are mostly related to oxidation and reduction mechanisms of selenium metabolites. Hydrogen selenide from selenite, and methylselenol (MSeH) from Se-methylselenocyteine (MSeC) and methylseleninicacid (MSeA) are the most reactive metabolites produced reactive oxygen species (ROS); furthermore, these metabolites may involve in oxidizing sulfhydryl groups, including glutathione. Selenite also reacted with glutathione and produces hydrogen selenide via selenodiglutathione (SeDG), which induces cytotoxicity as cell apoptosis, ROS production, DNA damage, and adenosine-methionine methylation in the cellular nucleus. However, a more pronounced effect was shown in the subsequent treatment of sodium selenite with chemotherapy and radiation therapy. High doses of sodium selenite were effective to increase radiation therapy and chemotherapy, and further to reduce radiation side effects and drug resistance. In our study, advanced cancer patients can tolerate until 5000 μg of sodium selenite in combination with radiation and chemotherapy since the half-life of sodium selenite may be relatively short, and, further, selenium may accumulates more in cancer cells than that of normal cells, which may be toxic to the cancer cells. Further clinical studies of high amount sodium selenite are required to treat advanced cancer patients.
APA, Harvard, Vancouver, ISO, and other styles
42

Catalano, Alessia, Domenico Iacopetta, Maria Stefania Sinicropi, and Carlo Franchini. "Diarylureas as Antitumor Agents." Applied Sciences 11, no. 1 (January 2, 2021): 374. http://dx.doi.org/10.3390/app11010374.

Full text
Abstract:
The diarylurea is a scaffold of great importance in medicinal chemistry as it is present in numerous heterocyclic compounds with antithrombotic, antimalarial, antibacterial, and anti-inflammatory properties. Some diarylureas, serine-threonine kinase or tyrosine kinase inhibitors, were recently reported in literature. The first to come into the market as an anticancer agent was sorafenib, followed by some others. In this review, we survey progress over the past 10 years in the development of new diarylureas as anticancer agents.
APA, Harvard, Vancouver, ISO, and other styles
43

Jones, G. B., and F. S. Fouad. "Designed Enediyne Antitumor Agents." Frontiers in Medicinal Chemistry - Online 1, no. 1 (January 1, 2004): 189–214. http://dx.doi.org/10.2174/1567204043396640.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Motohashi, Noboru, Sitaraghav R. Gollapudi, Jahangir Emrani, and Kesava R. Bhattiprolu. "Antitumor Properties of Phenothiazines." Cancer Investigation 9, no. 3 (January 1991): 305–19. http://dx.doi.org/10.3109/07357909109021328.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Nicoletti, Rosario, and Antonio Fiorentino. "Antitumor Metabolites of Fungi." Current Bioactive Compounds 10, no. 4 (February 6, 2015): 207–44. http://dx.doi.org/10.2174/1573407211666141224204809.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Santilli, Giorgia, John Anderson, Adrian J. Thrasher, and Arturo Sala. "Catechins and antitumor immunity." OncoImmunology 2, no. 6 (June 2013): e24443. http://dx.doi.org/10.4161/onci.24443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

MORIMOTO, MAKOTO, and RYOJI IMAI. "ANTITUMOR ACTIVITY OF ECHINOSPORIN." Journal of Antibiotics 38, no. 4 (1985): 490–95. http://dx.doi.org/10.7164/antibiotics.38.490.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Baixauli, Francesc, Matteo Villa, and Erika L. Pearce. "Potassium shapes antitumor immunity." Science 363, no. 6434 (March 28, 2019): 1395–96. http://dx.doi.org/10.1126/science.aaw8800.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

ISODA, Yoshihiro, Yukio NISHIZAWA, Shigehiko YAMAGUCHI, Jiro HIRANO, Akihiko YAMAMOTO, and Mitsuhiro NUMATA. "Antitumor Activity of Lipids." Journal of Japan Oil Chemists' Society 42, no. 11 (1993): 923–28. http://dx.doi.org/10.5650/jos1956.42.923.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Gresser, I. "Antitumor Effects of Interferon." Acta Oncologica 28, no. 3 (January 1989): 347–53. http://dx.doi.org/10.3109/02841868909111205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography